Aurinia Pharmaceuticals/AUPH

$5.78

1.04%
-
1D1W1MYTD1YMAX

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Ticker

AUPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Peter Greenleaf

Employees

300

Headquarters

Victoria, Canada

AUPH Metrics

BasicAdvanced
$827.21M
Market cap
-
P/E ratio
-$0.54
EPS
1.38
Beta
-
Dividend rate

What the Analysts think about AUPH

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
95.33% upside
High $15.00
Low $8.00
$5.78
Current price
$11.29
Average price target

AUPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-24.58% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$54.5M
31.64%
Net income
$-13.4M
17.54%
Profit margin
-24.58%
-10.72%

AUPH Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 16.33%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.18
-$0.08
-$0.09
-$0.19
-
Expected
-$0.22
-$0.18
-$0.17
-$0.16
-$0.14
Surprise
-18.71%
-56.36%
-46.15%
16.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aurinia Pharmaceuticals stock

Buy or sell Aurinia Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing